The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Over The Period 2026–2030?
The market for pharmaceutical contract development and manufacturing organizations (CDMOs) specializing in formulations has experienced significant expansion recently. This market is projected to expand from $54.73 billion in 2025 to $60.7 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 10.9%. Factors contributing to its historical growth include the scarcity of specialized peptide API manufacturers, a dependency on internal peptide manufacturing, an expanding pipeline of peptide therapeutics, stricter regulatory compliance demands, and the utilization of fundamental chemical synthesis techniques.
The market size for pharmaceutical contract development and manufacturing organizations (CDMOs) specializing in formulations is projected to experience swift expansion over the coming years. This market is anticipated to reach $90.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.6%. This projected growth during the forecast period is attributable to several factors, including breakthroughs in custom peptide synthesis technologies, the scaling up of commercial-grade GMP manufacturing, a rise in outsourcing to CROs and SMEs, the formulation of lifecycle management and process optimization strategies, and an escalating need for clinical and preclinical peptide API production. Key trends foreseen in this period involve a growing reliance on contract manufacturers for peptide API production, an increase in GMP-grade output for both clinical and commercial provisions, a heightened requirement for tailored peptide synthesis and purification solutions, the broadening of peptide therapeutics pipelines within pharmaceutical firms, and an emphasis on enhancing processes and managing the lifecycle of peptide APIs.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25876&type=smp
What Underlying Factors Are Accelerating The Growth Of The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?
The anticipated expansion of drug development and manufacturing initiatives is projected to drive the growth of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market. These activities encompass intensified efforts by pharmaceutical and biopharmaceutical firms to research, create, and produce novel medications. The primary reason for this increase is the escalating worldwide need for innovative and effective treatments, compelling companies to broaden their development portfolios and expedite production schedules. A pharmaceutical CDMO supports drug development through the formulation and optimization of dosage forms, conducting stability tests, and guaranteeing adherence to regulations. Furthermore, it oversees scale-up and manufacturing processes, facilitating quicker and more economical product introductions. For example, data from June 2023, released by the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade group representing the pharmaceutical industry in Europe, indicated that the total pharmaceutical output in Europe reached $422,803 million (€390,000 million) in 2023, an increase from $393,857 million (€363,300 million) in 2022. Consequently, the expansion in drug development and manufacturing initiatives is indeed fueling the growth of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market.
How Is The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Divided Into Its Major Segments?
The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market covered in this report is segmented –
1) By Dosage Form: Oral Solids, Oral Liquids, Injectables, Topicals, Inhalation Products, Transdermal And Patches, Other Dosage Forms
2) By Therapeutic Area: Oncology, Cardiology, Central Nervous System, Gastroenterology, Infectious Diseases, Endocrinology
3) By End-User: Pharmaceutical Companies, Biopharmaceutical Companies, Other End-Users
Subsegments:
1) By Oral Solids: Tablets, Capsules, Granules, Powders, Modified-Release Formulations
2) By Oral Liquids: Syrups, Suspensions, Solutions, Emulsions, Elixirs
3) By Injectables: Vials, Ampoules, Prefilled Syringes, Lyophilized Injections, Injectable Emulsions
4) By Topicals: Creams, Ointments, Gels, Lotions, Foams,
5) By Inhalation Products: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizer Solutions, Nasal Sprays, Inhalation Capsules
6) By Transdermal And Patches: Matrix Patches, Reservoir Patches, Drug-In-Adhesive Patches, Microneedle Patches, Iontophoretic Patches
7) By Other Dosage Forms: Suppositories, Ophthalmic Preparations, Buccal Tablets, Sublingual Tablets, Implants
How Are Trends Transforming The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Landscape?
Leading companies within the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market are concentrating on developing sophisticated solutions, such as biologic formulation platforms, to improve drug stability and expedite the market entry of complex biologic therapies. Biologic formulation platforms are specialized systems crafted to create stable and efficient formulations of biologic drugs. They precisely adjust elements like pH, excipients, and delivery methods to enhance stability, bioavailability, and safety across the product lifecycle. For instance, in June 2025, WuXi Biologics, a China-based contract research, development, and manufacturing organization, introduced WuXiHigh 2.0, a next-generation high-concentration formulation platform. This advanced platform enables biologic formulations with protein concentrations up to 230 mg/mL, exceeding the current Food and Drug Administration-approved maximum of 200 mg/mL, while reducing viscosity by up to 90% through proprietary excipient blends and high-throughput instrumentation. It addresses key challenges in developing high-concentration biologics, such as viscosity and aggregation, and is designed to improve injection efficiency, patient compliance, and manufacturing outcomes across clinical and commercial stages.
Who Are The Prominent Organizations Shaping The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market?
Major companies operating in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, Aarti Pharmalabs Limited.
Read the full pharmaceutical contract development and manufacturing organization (cdmo) for formulations market report here:
Which Region Is Projected To Dominate The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market During The Forecast Period?
Asia-Pacific was the largest region in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical contract development and manufacturing organization (cdmo) for formulations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25876&type=smp
Browse Through More Reports Similar to the Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market 2026, By The Business Research Company
Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026
Topical Drugs Contract Development And Manufacturing Organization Cdmo Market Report 2026
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization Cdmo Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model